ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Recommendation of “Moderate Buy” from Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has received a consensus recommendation of “Moderate Buy” from the eight brokerages that are covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $105.8333.

Several equities research analysts have recently weighed in on the company. Wall Street Zen downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Weiss Ratings cut ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Guggenheim cut their price objective on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Finally, Canaccord Genuity Group decreased their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research report on Monday, August 10th.

Insider Activity at ANI Pharmaceuticals

In related news, Director Thomas Haughey sold 2,000 shares of the firm’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.88, for a total value of $161,760.00. Following the transaction, the director owned 38,878 shares of the company’s stock, valued at $3,144,452.64. This trade represents a 4.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 3,162 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $77.00, for a total transaction of $243,474.00. Following the completion of the sale, the senior vice president directly owned 75,534 shares of the company’s stock, valued at approximately $5,816,118. This trade represents a 4.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 18,987 shares of company stock valued at $1,546,405. Company insiders own 8.10% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. KBC Group NV bought a new position in ANI Pharmaceuticals in the first quarter worth approximately $28,000. Advisors Asset Management Inc. bought a new stake in ANI Pharmaceuticals during the 1st quarter valued at $28,000. Hantz Financial Services Inc. raised its position in ANI Pharmaceuticals by 70.3% during the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after purchasing an additional 249 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new stake in shares of ANI Pharmaceuticals in the 4th quarter worth $48,000. Finally, State of Wyoming purchased a new stake in shares of ANI Pharmaceuticals in the 2nd quarter worth $50,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP opened at $75.35 on Wednesday. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals has a 12 month low of $70.15 and a 12 month high of $99.50. The company has a market capitalization of $1.73 billion, a price-to-earnings ratio of 16.24 and a beta of 0.44. The firm’s 50-day moving average is $80.36 and its 200 day moving average is $78.88.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The business had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. During the same quarter last year, the firm earned $1.80 earnings per share. The firm’s quarterly revenue was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Research analysts predict that ANI Pharmaceuticals will post 7.83 EPS for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.